"Authorized" Generics Will Be Subject To "Best Price" Calculations, CMS Suggests
This article was originally published in The Pink Sheet Daily
Executive Summary
Letter to GPhA from agency says that the products are considered innovator multiple source drugs, which would discourage the use of the practice by brand firms. CMS says it is reviewing its policy on calculation of prices for such products.
You may also be interested in...
CMS Seeks List Of "Authorized" Generics For Use In "Best Price" Reporting, GPhA Says
The Generic Pharmaceutical Association anticipates the National Governors Association's updated Medicaid recommendations will endorse the inclusion of authorized generics in Medicaid "best price" reporting. CMS has indicated it will consider adding authorized generics to its calculations.
CMS Seeks List Of "Authorized" Generics For Use In "Best Price" Reporting, GPhA Says
The Generic Pharmaceutical Association anticipates the National Governors Association's updated Medicaid recommendations will endorse the inclusion of authorized generics in Medicaid "best price" reporting. CMS has indicated it will consider adding authorized generics to its calculations.
FTC Should Study Competitive Impact Of "Authorized" Generics, Senators Say
Bipartisan group of senators requests investigation of the short- and long-term competitive impacts of "authorized" generics. Formal study request and remarks by one of the commissioners suggest the generic industry's arguments against the practice are gaining traction on Capitol Hill and at FTC.